Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-06 | 2024-03 | -0.23 | N/A | N/A | N/A |
2024-02-26 | 2023-12 | -0.24 | -0.28 | -0.04 | -16.67% |
2023-11-02 | 2023-09 | -0.25 | -0.19 | 0.06 | 24.00% |
2023-08-03 | 2023-06 | -0.25 | -0.24 | 0.01 | 4.00% |
2023-05-03 | 2023-03 | -0.3 | -0.28 | 0.02 | 6.67% |
2023-02-21 | 2022-12 | -0.19 | -0.38 | -0.19 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | RBC Capital | Upgrade | Outperform | Outperform |
2023-09-17 | RBC Capital | Upgrade | Sector Perform | Outperform |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-08-03 | Jefferies | Upgrade | Hold | Buy |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-02 | Needham | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-13 | BARNES ALANE P | Officer | 296.02K | Stock Award(Grant) |
2023-12-13 | DOYLE ANTHONY | Chief Financial Officer | 229.93K | Stock Award(Grant) |
2023-12-13 | GAYER CHARLES K | Officer | 277.02K | Stock Award(Grant) |
2024-02-28 | HEGGIE THERESA | Director | 51.86K | Stock Award(Grant) |
2023-06-13 | HUTSON NANCY J | Director | 81.82K | Sale |
2023-06-12 | LEVIN ALAN G | Director | 37.09K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 15.50M | 109.09M | 8.18% |
2023-06-29 | Vanguard Group Inc | 15.09M | 106.23M | 7.96% |
2023-06-29 | Baker Brothers Advisors, LLC | 12.71M | 89.48M | 6.71% |
2023-06-29 | State Street Corporation | 12.26M | 86.34M | 6.47% |
2023-06-29 | Avoro Capital Advisors LLC | 12.06M | 84.87M | 6.36% |
2023-06-29 | Assenagon Asset Management S.A. | 5.33M | 37.54M | 2.81% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 8.22M | 58.41M | 4.34% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 5.86M | 41.26M | 3.09% |
2023-08-30 | iShares Russell 2000 ETF | 4.29M | 30.51M | 2.26% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 2.81M | 19.96M | 1.48% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.58M | 18.14M | 1.36% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.44M | 17.17M | 1.29% |
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
-
What is this?
$FCEL is running faster than this.
I thought, I hit the jackpotMARONNN
-
-
Too much stressful for waiting
-
$BCRX I read somewhere down below it 4.70 and dooms day he’ll it 4.90 and blue sky ahead
-
-
$BCRX. Fry the shorts...
-
-
Hard pass $BCRX. 40,000 patients w a rare disease? Put a small position if anything. $COTY has kylie jenner w a winter product. $LLY has a drug release we just started using at our hospital here in Hawaii. If i ever met someone w this disease, id invest. $GTBIF $SNX for Concentrix splitting off and thats cloud plus healthcare w a 69% CAGR on Dec 1st
-
The launch of Orladeyo is exciting for patients, exciting for physicians and exciting for BioCryst. Oral drugs for rare diseases really matter. At BioCryst, we discover, develop and commercialize oral medicines for rare diseases. $BCRX this? Why is this trending?
-
-
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. $IBIO shares price in past pandemics 15$-55$, $IBIO conference is Monday
-
History $IBIO made money in all the pandemics, share price in pandemics was between 15$and 55$, big conference is coming, $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come.
-
History $IBIO made money from all pandemics,was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come.
-
$AIKI guys. Cancer drug news today. Will likely pop more tomorrow.
-
$IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. This will be remembered for the rest of our lives. Also If people Will take the COVID-19 vaccine,they will trust and prefer a vaccine made of plants$IBIO has the best and most advanced technology at the moment
-
-
-
-
BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month Low at $4.15
news.google.com • -
BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month Low at $4.15
news.google.com • -
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month Low at $4.44
news.google.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report Third Quarter 2023 Financial Results on November 2
globenewswire.com • -
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
proactiveinvestors.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Second Quarter 2023 Financial Results on August 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst to Report First Quarter 2023 Financial Results on May 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Good Candidate For Buyout, But Not For Anything Else
seekingalpha.com • -
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
globenewswire.com • -
Pharmaceutical Stock Sinks on Sales Forecast
schaeffersresearch.com • -
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
globenewswire.com • -
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
seekingalpha.com • -
BCRX Stock Sinks as BioCryst Discontinues Drug Development
investorplace.com • -
BioCryst to discontinue development of drug
marketwatch.com • -
BioCryst to Present at JMP Securities Hematology & Oncology Summit
globenewswire.com • -
3 Biotechnology stocks under 10 dollars to buy now
thedogofwallstreet.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Third Quarter 2022 Financial Results on November 1
globenewswire.com • -
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com •